Pharmaceuticals

Drug Development Drug Pricing Drug Approval Drug Safety Clinical Trials Weight Loss Drugs Prescription Drugs Biotechnology Drug Regulation Drug Manufacturing

White House Adds More Than 600 Generics to TrumpRx and Links Site to Cost Plus, Amazon and GoodRx

The update routes consumers to private cash‑pay pharmacies so lower list prices may not reduce insured patients’ out‑of‑pocket costs.

Jury Finds Takeda Liable for Delaying Amitiza Generics, Awards $885 Million

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

Gossamer Bio Hit With Investor Class Action After PROSERA Miss, With June 1 Lead‑Plaintiff Deadline

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Supreme Court Blocks 5th Circuit, Keeps Abortion Pill Mail Access for Now

HCW Biologics Posts Surprise Q1 Profit on Trimmune Deal as Listing Risk Lingers

Fennec Q1 Sales Climb 73% to $15.1 Million on PEDMARK Momentum

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Hims & Hers Lifts Sales Outlook as GLP‑1 Pivot Squeezes Profits

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

Milestone Posts Q1 Loss as CARDAMYST Launch Shows Early Uptake and AFib-RVR Phase 3 Begins

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

PolyPid Nears Completion of Rolling FDA Filing for D‑PLEX100

Supreme Court Extends Pause on Abortion Pill Limits to May 14

Verrica Reports $5 Million Q1 Revenue as Wycanth Grows and Phase 3 Wart Program Advances

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

Trump Revives 'Fat Drug' Anecdote, Mocks Friend While Pushing GLP-1 Price Claims